[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"b-cell-non-hodgkins-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:b-cell-non-hodgkins-lymphoma":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,64,94,117,141,167,188,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100578033","phase-2-a-study-to-evaluate-the-optimization-of-the-cytokine-release-syndrome-profile-for-glofitamab-in-combination-with-gemcitabine-plus-oxaliplatin-in-participants-with-relapsedrefractory-aggressive-b-cell-non-hodgkins-lymphoma-100578033",false,"NCT06806033","A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed\u002FRefractory Aggressive B-Cell Non-Hodgkin's Lymphoma","A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed\u002FRefractory Aggressive B-Cell Non-Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Histologically confirmed large B-cell lymphoma (de novo or transformed from FL) with one of the following diagnoses according to World Health Organization, fifth edition: DLBCL Not Otherwise Specified (NOS); High-Grade B-Cell Lymphoma (HGBL), NOS; DLBCL\u002FHGBL with MYC and BCL2 rearrangements\n* R\u002FR disease, defined as: relapsed = disease that has recurred following a response that lasted \\>\u002F= 6 months after completion of the last line of therapy; refractory = disease that did not respond to or that progressed \\\u003C 6 months after completion of the last line of therapy\n* At least one line of prior systemic therapy\n* Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)\n* At least one bi-dimensionally measurable (\\> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (\\> 1 cm) extranodal lesion, as measured on CT scan\n* Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2\n* According to the investigator's judgment, participants should be able to receive the step-up dose regimen in an outpatient setting\n* Adequate hematologic and renal function\n\nExclusion Criteria:\n\n* Prior enrollment in Studies GO41943 (NCT04313608), GO41944 (STARGLO; NCT04408638), or Study GO44900 (NCT06624085)\n* Participant has failed only one prior line of therapy and is a candidate for stem cell transplantation\n* Any history of Waldenstrom's macroglobulinemia\n* Primary mediastinal B-cell lymphoma\n* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products\n* Contraindication to obinutuzumab, gemcitabine or oxaliplatin, or tocilizumab\n* Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3\n* Prior treatment with gemcitabine or oxaliplatin\n* Peripheral neuropathy or paresthesia assessed to be Grade \\>\u002F= 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 at enrollment\n* Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment\n* Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment\n* Primary or secondary CNS lymphoma at the time of recruitment\n* Prior CNS involvement that has been definitively treated and confirmed via magnetic resonance imaging (MRI) or cerebrospinal fluid analysis to be in complete remission is permissible\n* Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* History of other primary malignancy, with exceptions defined by the protocol\n* Significant or extensive cardiovascular disease\n* Significant pulmonary disease (including moderate or severe obstructive pulmonary disease)\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 4 weeks prior to the first study treatment\n* Positive for: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); chronic active Epstein-Barr viral infection\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH) or progressive multifocal leukoencephalopathy\n* Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better (with the exception of alopecia and anorexia)\n* Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study\n* Prior solid organ transplantation or prior allogenic stem cell transplant\n* Active autoimmune disease requiring treatment\n* Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor agents), within 4 weeks prior to first dose of study treatment\n* Ongoing systemic corticosteroid use which, in the opinion of the investigator, puts the participant at increased risk of steroid-related iatrogenic adrenal insufficiency\n* Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis\n* Clinically significant history of cirrhotic liver disease\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high-risk from treatment complications\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 18 months after the final dose of study treatment","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.",[26],"B-Cell Non-Hodgkins Lymphoma",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Phase 2","Outpatient study","Open-label","Glofitamab","Gemcitabine","Oxaliplatin","Obinutuzumab","GemOx","Glofit-GemOx","Bispecific antibody","Aggressive B-cell Non-Hodgkin's lymphoma","Diffuse Large B-Cell Lymphoma (DLBCL)","DLBCL NOS (Not Otherwise Specified)","High-Grade B-Cell Lymphoma (HGBL)","HGBL NOS","Transformed follicular lymphoma","DLBCL\u002FHGBL with MYC and BCL2 rearrangements","Double-hit lymphoma","Relapsed or Refractory (R\u002FR)","Non-Hodgkin Lymphoma (NHL)","Cytokine Release Syndrome (CRS)","CRS optimization","Step-up dosing","RECRUITING","2026-06-18",{"date":54,"type":55},"2026-06-23","ACTUAL",{"date":57,"type":55},"2025-03-05",{"date":59,"type":20},"2029-03-30",{"name":61,"class":62},"Hoffmann-La Roche","INDUSTRY",53,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100611341","phase-1-in-vivo-car-t-therapy-for-relapsedrefractory-hematological-malignancies-100611341","NCT07239323","In VIVO CAR-T Therapy for Relapsed\u002FRefractory Hematological Malignancies","Intracellularly Prepared Chimeric Antigen Receptor T-cell Therapy Targeting CD19 for the Treatment of Relapsed\u002FRefractory Hematological Malignancies","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender unrestricted;\n2. Confirmed diagnosis of relapsed\u002Frefractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma;\n3. ECOG performance status score 0-2, with an expected survival period of ≥ 3 months;\n4. Blood routine test results during the screening period meet the following criteria:\n\n   ① Hemoglobin ≥ 6 g\u002FdL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin (rhEPO) is allowed; for patients meeting the hemoglobin ≥ 6 g\u002FdL criterion, red blood cell transfusion can be used to maintain hemoglobin ≥ 6 g\u002FdL;\n   * Absolute neutrophil count (ANC) ≥ 600\u002FμL (no use of granulocyte colony-stimulating factor \\[G-CSF\\] within 1 week before screening, or no use of pegylated G-CSF within 2 weeks before screening); ③ Platelet count ≥ 50,000\u002FμL; ④ Lymphocyte count ≥ 500\u002FμL;\n5. Normal renal function during the screening period: creatinine clearance rate (CrCl) ≥ 45 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n6. Liver function during the screening period meets the following criteria:\n\n   ① Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3.0 × ULN;\n\n   ② Total bilirubin (TBIL) ≤ 2.0 × ULN (except for congenital hyperbilirubinemia such as Gilbert's syndrome, direct bilirubin can be relaxed to ≤ 1.5 × ULN);\n7. Cardiac function during the screening period meets the following criteria:\n\n   ① Left ventricular ejection fraction (LVEF) ≥ 40% (measured by echocardiography or MUGA scan);\n\n   ② No clinically significant pericardial effusion;\n\n   ③ No clinically significant electrocardiogram (ECG) abnormalities;\n8. Pulmonary function during the screening period meets the following criteria: blood oxygen saturation (SpO₂) ≥ 90%;\n9. Women of childbearing age must have a negative pregnancy test during the screening period and before drug administration, and must not be in the lactation period;\n10. Men and women of childbearing age must agree to take effective contraceptive measures and not donate reproductive cells (including sperm or eggs) from the time of signing the informed consent form until 1 year after the end of study drug administration;\n11. The subject or their legally authorized representative has signed the informed consent form (ICF), indicating their understanding of the purpose and procedures of the study and their voluntary participation in this study.\n\nExclusion Criteria:\n\n1. Other anti-tumor treatments within the screening period (judged by the investigator comprehensively):\n\n   ① Received chemotherapy, targeted therapy or immunotherapy within 5 half-lives before administration;\n\n   ② Received radiotherapy within 4 weeks before administration (if the radiotherapy target area covers ≤ 5% of bone marrow reserve, the time limit for radiotherapy completion is not restricted);\n2. History of hematopoietic stem cell transplantation: Received allogeneic or autologous hematopoietic stem cell transplantation within 3 months before administration;\n3. History of other malignant tumors (except for this disease), except for the following situations:\n\n   ① Received radical treatment and had no known active disease for ≥ 2 years before enrollment;\n\n   ② Had fully treated non-melanoma skin cancer in the past and had no active lesions at present;\n4. Received treatment related to vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus in the past;\n5. Had severe and uncontrolled infections (bacterial, viral, fungal, etc.) within the screening period;\n6. Clinically significant cardiac diseases:\n\n   * Had symptomatic heart failure or other serious cardiac diseases (such as severe arrhythmia);\n\n     * Had New York Heart Association (NYHA) Class III-IV congestive heart failure; ③ Had a myocardial infarction or received coronary artery bypass grafting (CABG) \u002F coronary artery stent implantation within 6 months before signing the informed consent;\n\n       * Had clinically significant ventricular arrhythmia or a history of unexplained syncope; ⑤ Had a history of syncope (excluding cases caused by vasovagal reactions or dehydration); ⑥ Had a history of severe non-ischemic cardiomyopathy;\n7. Other clinically significant diseases, including but not limited to:\n\n   * Primary immunodeficiency; ② Had a stroke or seizure within 6 months before screening;\n\n     * Had clear clinical evidence of dementia or mental status changes; ④ Had Parkinson's disease, Parkinson-like movement disorders or a history of the above;\n8. Had undergone surgery within 2 weeks before administration, or planned to undergo surgery within 2 weeks after administration (local anesthesia surgery excluded);\n9. Had received live attenuated vaccines within 1 month before administration;\n10. Had a history of severe allergic reactions to this product or its formulation components;\n11. Patients who were not suitable for establishing intravenous access;\n12. The investigator believed that there were other conditions that made the patient unsuitable for participating in this study.",{"count":72,"type":20},24,[74],"PHASE1","This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.\n\nIt is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.",[77,78,79],"B-Acute Lymphoblastic Leukemia","B Cell Non-Hodgkin's Lymphoma","Multiple Myeloma",[81,82,83],"in Vivo","CAR-T","malignant hematological tumors","2025-11-16",{"date":86,"type":55},"2025-11-20",{"date":88,"type":55},"2025-07-01",{"date":90,"type":20},"2028-12-31",{"name":92,"class":62},"Chongqing Precision Biotech Co., Ltd",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":93},"100599171","phase-2-js203-combination-regimens-in-b-cell-non-hodgkins-lymphoma-100599171","NCT07081022","JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be enrolled：\n\n* Age range: 18 to 80 years old (inclusive), both male and female are acceptable；\n* ECOG: 0-2；\n* B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed；\n* At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening；\n\nExclusion Criteria:\n\n* A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；\n* Previously received CD20-CD3 bispecific antibody treatment；\n* Previous allogeneic hematopoietic stem cell transplantation；\n* Previous solid organ transplantation；\n* History of autoimmune diseases；\n* Patients with a history of macrophage activation syndrome (MAS)\u002F hemophagocytic lymphohistiocytosis (HLH)；\n* Patients with a history of progressive multifocal leukoencephalopathy (PML)；\n* A known or suspected history of CNS lymphoma (including primary or secondary)；\n* There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；","80 Years",{"count":102,"type":20},180,[23],"To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma",[106],"B-cell Non-Hodgkin's Lymphoma","2025-08-20",{"date":109,"type":55},"2025-08-21",{"date":111,"type":55},"2025-08-17",{"date":113,"type":20},"2027-04-06",{"name":115,"class":116},"Shanghai Junshi Bioscience Co., Ltd.","OTHER",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100584848","phase-1-a-phase-i-clinical-trial-of-rs001-in-patients-with-relapsedrefractory-b-cell-malignancies-100584848","NCT06894693","A Phase I Clinical Trial of RS001 in Patients with Relapsed\u002FRefractory B-Cell Malignancies","A Phase I Clinical Trial of RS001 in Patients with Relapsed\u002FRefractory B-Cell Malignancies:","Inclusion Criteria:\n\n1. Voluntarily sign an ICF and expect to complete the subsequent follow-up.\n2. Aged 18 to 75 years (including cut-offs), regardless of gender.\n3. Meet one of the following B-cell malignancies:\n\n\u003C!-- -->\n\n1. . B-cell non-Hodgkin's lymphoma diagnosed as CD19-positive by cytology or histopathology according to WHO 2022 criteria, including pathologically confirmed (1) diffuse large B-cell lymphoma, non-specific type (DLBCL, NOS); (2) follicular lymphoma histopathologically graded as grade 3b (FL3b); (3) follicular lymphoma with diffuse large B-cell transformation; (4) primary mediastinal large B-cell lymphoma (PMBCL); (5) high-grade B-cell lymphoma (HGBCL).\n\n   1. Relapsed\u002Frefractory B-cell non-Hodgkin lymphoma, defined as meeting one or more of the following criteria:\n\n      \\- Definition of relapse: Relapse after achieving remission (PR and CR) with second-line or higher therapy;\n      * Definition of refractory: No response to second-line or more therapy: The best efficacy of last therapy is PD or SD (SD requires at least 2 cycles of treatment); Recurrence (must have biopsy-proven recurrence) or progression within 12 months of autologous stem cell transplantation (ASCT) . If salvage therapy, no response to last therapy (SD or PD).\n   2. Subjects must have received adequate treatment in the past, which should include the following treatments:\n\n      * Anti-CD20 monoclonal antibody, unless the investigator determines that the tumor is CD20 negative;\n      * Chemotherapy containing anthracycline drugs;\n      * For subjects with transformed follicular lymphoma (tFL) who have been previously treated with follicular lymphoma (FL) chemotherapy and with transformation to DLBCL show refractory to chemotherapy.\n   3. ECOG performance status 0 to 1.\n   4. The presence of a measurable lesion that meets one of the following criteria:\n\n      * The long axis of the lymph node lesion exceeds 15 mm in length (the short axis is measurable);\n      * The long and short axes of the extralymph node lesion exceed 10 mm in length.\n2. Relapsed\u002Frefractory B-cell acute lymphoblastic leukemia must meet the following requirements:\n\n   1. Relapsed: Recurrence within 12 months after the first remission;\n   2. Refractory: i. failure to remit after more than 6 weeks of induction therapy or failure to remit after two courses of induction therapy; ii. relapse after 2 or more CRs; iii. first relapse after chemotherapy and failure to remit after having received at least 1 salvage therapy; iv. relapse after autologous hematopoietic stem cell transplantation;\n   3. Prior to screening, leukemia cells expressing CD19 are detectable in bone marrow or peripheral blood.\n   4. Ph+ ALL patients who have failed treatment with at least 2 tyrosine kinase inhibitor (TKI) drugs (including at least 1 2nd generation TKI drug) or are intolerant of drug-related side effects such as allergy to components of the TKI class of drugs, blood abnormalities, liver or kidney impairment, severe cardiovascular toxicity, and other drug-related side effects that prevent them from continuing to be a user; If the patient has the T315I mutation, TKI salvage therapy is not required;\n   5. The proportion of primitive and naïve lymphocytes in bone marrow during the screening period ≥5%; 4. Laboratory results within 7 days prior to Lymphodepletion need to meet the following criteria:\n\n   \u003C!-- -->\n\n   1. Coagulation function:\n\n      \\- Activated partial thromboplastin time ≤ 1.5 times the upper limit of normal (ULN);\n\n      \\- Prothrombin time (PT) ≤ 1.5 times ULN;\n   2. Liver function:\n\n      \\- Glutathione aminotransferase (AST) ≤ 5 times the upper limit of normal (ULN);\n\n      \\- Total bilirubin ≤ 1.5 times ULN, unless the subject has documented Gilbert syndrome;\n\n      \\- Subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN may be included.\n   3. Renal function: Serum creatinine ≤ 1.5 times ULN or a creatinine clearance ≥ 60 ml\u002Fmin;\n   4. Complete blood count (No blood transfusion treatment received within 7 days prior to examination):\n\n      \\- Haemoglobin ≥ 80 g\u002FL;\n\n      \\- Absolute neutrophil count (ANC) ≥ 1.0 x 10\\^9\u002FL;\n      * A platelet count ≥ 50 x 10\\^9\u002FL;\n   5. Cardiopulmonary function:\n\n      * Left ventricular ejection fraction (LVEF) ≥ 45%;\n      * Oxygen saturation ≥ 91%; 5. Female subjects with of childbearing potential should have a negative pregnancy test during the screening period. Any male and female subjects of childbearing potential must agree to use an effective contraception method for at least six months from the time that they sign the informed consent form until the end of the cell infusion. Female subjects without childbearing potential (meeting at least 1 of the following criteria) is described below:\n\n   a. Have undergone a hysterectomy or bilateral oophorectomy; b. Medically recognised ovarian failure; c. Medically recognised as post-menopausal (at least 12 consecutive months of menopause without pathological or physiological cause).\n\nExclusion Criteria:\n\n1. Other malignancies within 5 years prior to screening, except adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, post-radical localized prostate cancer, post-radical ductal carcinoma in situ, and post-radical thyroid cancer;\n2. Any unstable systemic disease: including but not limited to active infection (other than local infection), unstable angina, cerebrovascular accident or transient ischaemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association class III or IV cardiac insufficiency, refractory hypertension (refractory hypertension is defined as blood pressure that has not reached standard after \\>1 month of reasonably tolerable treatment with ≥3 antihypertensive drugs (including diuretics) at adequate doses based on lifestyle improvement or blood pressure that is not effectively controlled with ≥4 antihypertensive drugs), severe cardiac arrhythmias requiring pharmacologic treatment, hepatic arrhythmias, liver diseases, kidney diseases or metabolic disorders;\n3. Patients with B-cell non-Hodgkin's lymphoma with active central nervous system invasion.\n4. Patients with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titres not within the normal reference range, positive hepatitis C virus (HCV) antibody and peripheral blood HCV RNA ,positive for human immunodeficiency virus (HIV), or positive for cytomegalovirus (CMV) DNA, or positive syphilis test.\n5. Subjects who are receiving systemic steroids prior to screening and who are judged by the investigator to require long-term treatment with systemic steroids during the treatment period (except for inhaled or topical use).\n6. Previous organ transplantation or preparation for organ transplantation (except for haematopoietic stem cell transplantation).\n7. Persons with acute\u002Fchronic Graft-vs-Host Disease (GvHD).\n8. Patients have received a haematopoietic stem cell transplant within 2 months prior to screening.\n9. Patients who have previously received any CD19-CAR-T\u002FNK cell therapy, or received CAR-T\u002FNK cell therapy targeting other antigens within the three months prior to screening.\n10. Active neurological autoimmune or inflammatory diseases (e.g. Guillain-Barre Syndrome (GBS), Amyotrophic lateral sclerosis (ALS)).\n11. Clinically significant active cerebrovascular diseases (such as cerebral edema, posterior reversible encephalopathy syndrome).\n12. Patients with a life expectancy of less than 3 months.\n13. Participants who have previously been involved in other interventional clinical studies and received active investigational drugs, with the last use of an unapproved new drug being less than 28 days prior to signing the informed consent for this trial, or the last use of an approved drug being less than five half-lives prior to cell infusion.\n14. Received attenuated live vaccine within 6 weeks prior to lymphodepletion.\n15. The subjects have contraindications or hypersensitivity reactions to fludarabine, cyclophosphamide, tocilizumab, investigational product and its ingredients.\n16. Remaining within the washout period of other antitumor treatments prior to lymphodepletion.\n17. Patients who, in the investigator's judgment and\u002For clinical criteria, have a contraindication to any of the study procedures or have other medical conditions that may place them at unacceptable risk.","75 Years",{"count":126,"type":20},13,[74],"This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in subjects with CD19-positive relapsed\u002Frefractory B-cell malignancies (BCM).",[106,130],"Acute Lymphoblastic Leukemia","NOT_YET_RECRUITING","2025-03-18",{"date":134,"type":55},"2025-03-25",{"date":136,"type":20},"2025-04-01",{"date":138,"type":20},"2028-04-01",{"name":140,"class":62},"Guangdong Ruishun Biotech Co., Ltd",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100540283","phase-1-a-tolerability-safety-and-efficacy-study-of-rjmty19-in-subjects-with-relapsed-or-refractory-b-nhl-100540283","NCT06314828","A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL","A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)","Inclusion Criteria:\n\n1. Voluntarily sign an ICF and expect to complete the subsequent follow-up.\n2. Aged 18 to 65 years (including cut-offs), regardless of gender.\n3. B-cell non-Hodgkin's lymphoma diagnosed as CD19-positive by cytology or histopathology according to WHO 2022 criteria, including pathologically confirmed (1) diffuse large B-cell lymphoma, non-specific type (DLBCL, NOS); (2) follicular lymphoma histopathologically graded as grade 3b (FL3b); (3) follicular lymphoma with diffuse large B-cell transformation; (4) primary mediastinal large B-cell lymphoma (PMBCL); (5) high-grade B-cell lymphoma (HGBCL).\n4. Relapsed\u002Frefractory B-cell non-Hodgkin's lymphoma, provided one of the following conditions is met:\n\n   1. Definition of relapse: Relapse after achieving remission (PR and CR) with second-line or higher therapy;\n   2. Definition of refractory:\n\n      * No response to second-line or more therapy: The best efficacy of last therapy is PD or SD (SD requires at least 2 cycles of treatment);\n      * Recurrence (must have biopsy-proven recurrence) or progression within 12 months of autologous stem cell transplantation (ASCT) . If salvage therapy, no response to last therapy (SD or PD).\n5. Subjects must have received adequate treatment in the past, which should include the following treatments:\n\n   1. Anti-CD20 monoclonal antibody, unless the investigator determines that the tumor is CD20 negative;\n   2. Chemotherapy containing anthracycline drugs;\n   3. For subjects with transformed follicular lymphoma (tFL) who have been previously treated with follicular lymphoma (FL) chemotherapy and with transformation to DLBCL show refractory to chemotherapy.\n6. ECOG performance status 0 to 1.\n7. The presence of a measurable lesion that meets one of the following criteria:\n\n   1. The long axis of the lymph node lesion exceeds 15 mm in length (the short axis is measurable);\n   2. The long and short axes of the extralymph node lesion exceed 10 mm in length.\n8. ALaboratory results within 7 days prior to Lymphodepletion need to meet the following criteria:\n\n   1. Coagulation function:\n\n      * Activated partial thromboplastin time ≤ 1.5 times the upper limit of normal (ULN);\n      * Prothrombin time (PT) ≤ 1.5 times ULN;\n   2. Liver function:\n\n      * Glutathione aminotransferase (AST) ≤ 5 times the upper limit of normal (ULN);\n      * Glutamic aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN);\n      * Total bilirubin ≤ 1.5 times ULN, unless the subject has documented Gilbert syndrome;\n      * Subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN may be included.\n   3. Renal function:\n\n      * Serum creatinine ≤ 1.5 times ULN or a creatinine clearance ≥ 60 ml\u002Fmin;\n   4. Complete blood count (No blood transfusion treatment received within 7 days prior to examination):\n\n      * Haemoglobin ≥ 80 g\u002FL;\n      * Absolute neutrophil count (ANC) ≥ 1.0 x 10\\^9\u002FL;\n      * A platelet count ≥ 50 x 10\\^9\u002FL;\n   5. Cardiopulmonary function:\n\n      * Left ventricular ejection fraction (LVEF) ≥ 45%;\n      * Oxygen saturation ≥ 91%;\n9. Female subjects with of childbearing potential should have a negative pregnancy test during the screening period. Any male and female subjects of childbearing potential must agree to use an effective contraception method for at least six months from the time that they sign the informed consent form until the end of the cell infusion. Female subjects without childbearing potential (meeting at least 1 of the following criteria) is described below:\n\n   1. Have undergone a hysterectomy or bilateral oophorectomy;\n   2. Medically recognised ovarian failure;\n   3. Medically recognised as post-menopausal (at least 12 consecutive months of menopause without pathological or physiological cause).\n\nExclusion Criteria:\n\n1. Other malignancies within 5 years prior to screening, except adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, post-radical localized prostate cancer, post-radical ductal carcinoma in situ, and post-radical thyroid cancer\n2. Any unstable systemic disease: including but not limited to active infection (other than local infection), unstable angina, cerebrovascular accident or transient ischaemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association class III or IV cardiac insufficiency, refractory hypertension (refractory hypertension is defined as blood pressure that has not reached standard after \\>1 month of reasonably tolerable treatment with ≥3 antihypertensive drugs (including diuretics) at adequate doses based on lifestyle improvement or blood pressure that is not effectively controlled with ≥4 antihypertensive drugs), severe cardiac arrhythmias requiring pharmacologic treatment, hepatic arrhythmias, liver diseases, kidney diseases or metabolic disorders.\n3. Patients with B-cell non-Hodgkin's lymphoma with active central nervous system invasion.\n4. Patients with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titres not within the normal reference range, positive hepatitis C virus (HCV) antibody and peripheral blood HCV RNA ,positive for human immunodeficiency virus (HIV), or positive for cytomegalovirus (CMV) DNA, or positive syphilis test.\n5. Subjects who are receiving systemic steroids prior to screening and who are judged by the investigator to require long-term treatment with systemic steroids during the treatment period (except for inhaled or topical use).\n6. Previous organ transplantation or preparation for organ transplantation (except for haematopoietic stem cell transplantation).\n7. Persons with acute\u002Fchronic Graft-vs-Host Disease (GvHD).\n8. Patients have received a haematopoietic stem cell transplant within 2 months prior to screening.\n9. Active neurological autoimmune or inflammatory diseases (e.g. Guillain-Barre Syndrome (GBS), Amyotrophic lateral sclerosis (ALS)).\n10. Clinically significant active cerebrovascular diseases (such as cerebral edema, posterior reversible encephalopathy syndrome).\n11. Patients with a life expectancy of less than 3 months.\n12. Subjects have participated in other interventional clinical studies within 3 months prior to screening.\n13. Received attenuated live vaccine within 6 weeks prior to lymphodepletion.\n14. The subjects have contraindications or hypersensitivity reactions to fludarabine, cyclophosphamide, etoposide, tocilizumab, investigational product and its ingredients.\n15. Remaining within the washout period of other antitumor treatments prior to lymphodepletion.\n16. Patients who, in the investigator's judgment and\u002For clinical criteria, have a contraindication to any of the study procedures or have other medical conditions that may place them at unacceptable risk.","65 Years",{"count":150,"type":20},30,[74],"This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r\u002Fr B-NHL.",[106],[155,156,157,158],"off-the-shelf cell product","CAR-DNT","Cell Therapy","B-NHL","2024-03-11",{"date":161,"type":55},"2024-03-18",{"date":163,"type":20},"2024-05-20",{"date":165,"type":20},"2027-05-20",{"name":140,"class":62},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":93},"100524118","phase-1-a-trial-of-shr-a1912-combined-with-other-therapies-in-b-cell-non-hodgkin-s-lymphoma-100524118","NCT06104553","A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma","A Phase Ib\u002FII Study of SHR-A1912 Combined With Other Therapies in Patients With B-cell Non-Hodgkin 's Lymphoma","Inclusion Criteria:\n\n1. Age greater than or equal to18 years old;\n2. Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1;\n3. Life expectancy \\>3 months;\n4. Histologically confirmed B-cell B-cell non-Hodgkin's lymphoma;\n5. Previous systematic anti-tumor therapy should meet the following requirements: 1) Relapsed and\u002For refractory disease after at least one (≥ 1) line of prior systemic therapy (relapsed\u002Frefractory cohort); 2) Previously untreated (naïve cohort).\n6. At least one measurable nodal lesion, defined as \\> 1.5 cm in its longest dimension, or one measurable extra nodal lesion, defined as \\> 1.0 cm in its longest diameter.\n\nExclusion Criteria:\n\n1. Received autologous stem cell transplantation within 12 weeks before the first study treatment; previously received allogeneic stem cell transplantation; received Car-T cell therapy within 12 weeks before the first study treatment;\n2. History of recent major surgery or severe trauma within 4 weeks before the first study treatment;\n3. Received anti-tumour treatment within 2 weeks before the first study treatment;\n4. Central nervous system (CNS) infiltration;\n5. Active infection with HBV or HCV;\n6. History of immunodeficiency, including HIV serotest positive, or other acquired or congenital immunodeficiency diseases, and active tuberculosis;\n7. Active infection or unexplained fever\\>38.5℃;\n8. History of severe cardiovascular disease.",{"count":175,"type":20},132,[74,23],"This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.",[106],"2023-12-20",{"date":181,"type":55},"2023-12-27",{"date":183,"type":55},"2023-11-17",{"date":185,"type":20},"2026-06",{"name":187,"class":62},"Shanghai Hengrui Pharmaceutical Co., Ltd.",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":93},"100472772","phase-2-human-cd19-targeted-t-cells-injectioncd19-car-t-therapy-for-relapsed-and-refractory-b-cell-non-hodgkins-lymphoma-100472772","NCT05436223","Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma","A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma","Inclusion Criteria:Subjects with relapsed\u002Frefractory B-cell non-Hodgkin's lymphoma\n\n* Age≥18 years old，gender is not limited;\n* Expected survival \\> 12 weeks;\n* ECOG score 0-2;\n* B-cell non-Hodgkin's lymphoma confirmed by cytology or histopathology according to the 2016 World Health Organization (WHO) classification and diagnostic criteria, including: diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed filter Alveolar lymphoma (TFL) and high-grade B-cell lymphoma (HGBCL);\n* Pathology demonstrated that B-cell non-Hodgkin's lymphoma and who meet one of the following conditions:\n\n  1. Relapsed and refractory B-cell non-Hodgkin's lymphoma, after standard first-line treatment and at least 2 courses of second-line treatment without remission and relapse (the previous use of CD20-targeted drugs and anthracyclines were needed);\n  2. Relapse of B-cell non-Hodgkin lymphoma after stem cell transplantation, regardless of previous treatments.\n* The venous access required for collection can be established and leukepheresis can be carried according to the judgement of investigators, satisfying hemoglobin≥80g\u002FL, neutrophils ≥1.0×10\\^9\u002FL, platelets ≥75×10\\^9 \u002F L;\n* According to the Lugano 2014 criteria, there should be at least one measurable tumor lesion;\n* Liver, kidney and cardiopulmonary functions meet the following requirements:\n\n  1. Serum creatinine≤1.5×ULN or creatinine clearance rate≥50mL\u002Fmin (GockcroftGault formula);\n  2. Cardiac ejection fraction \\>50%, no clinically significant pericardial effusion detected, no clinically significant pleural effusion detected;\n  3. Baseline blood oxygen saturation\\>92%;\n  4. Total bilirubin≤1.5×ULN(Gilbert syndrome≤5×ULN);\n  5. ALT and AST≤3×ULN (AST and ALT ≤5×ULN in patients with liver metastases);\n* Able to understand and sign the Informed Consent Document.\n\nExclusion Criteria:Any one of the following conditions cannot be selected as a subject：\n\n* Malignant tumors other than diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and high-grade B-cell lymphoma (HGBCL) within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection and thyroid cancer after radical resection ;\n* Subjects with positive Hepatitis B surface antigen(HBsAg) or Hepatitis B core antibody (HBcAb) and positive peripheral blood hepatitis B virus (HBV) DNA titers (higher than the upper limit of the normal range of the investigative site); Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human Immunodeficiency Viral (HIV) antibody positive; syphilis positive;\n* Any uncontrolled systemic diseases, including but not limited to active infection (except for localized infection), uncontrolled angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;\n* Any other uncontrolled active disease that precludes participation in the trial;\n* Any circumstances that the investigator believes will compromise the safety of the subject or interfere with the purpose of the study;\n* Pregnant or lactating woman, or planned pregnancy during treatment or within 1 year after treatment, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;\n* Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment (except uncomplicated urinary tract infection or upper respiratory tract infection);\n* Subjects who were receiving systemic steroid treatment within 14 days before enrollment and who were judged by the investigator to require long-term use of systemic steroid therapy during treatment (except inhalation or topical use); or subjects who received any systemic anti-tumor therapy ( except for local anti-tumor therapy) ;\n* Subjects who have received CAR-T treatment or other gene-modified cell therapy before enrollment;\n* Patients with symptoms of central nervous system or brain metastasis or have received treatment for central nervous system or brain metastasis (radiotherapy, surgery or other treatment) within 3 months before enrollment;\n* Subjects who have a disease that affects the signing of written informed consent or who are unable to comply with research procedures; or who are unwilling or unable to comply with research requirements;\n* Subjects who are considered unsuitable to participate in this trial by the investigator.",{"count":19,"type":20},[23],"A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R\u002FR B-NHL.\n\nPatients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.",[106],[200,201,82,202],"B-cell non-Hodgkin's Lymphoma","CD19","Relapsed\u002FRefractory","2022-06-29",{"date":205,"type":55},"2022-07-05",{"date":207,"type":55},"2021-08-09",{"date":209,"type":20},"2026-08-09",{"name":211,"class":62},"Hrain Biotechnology Co., Ltd.",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100446292","phase-1-a-phase-12-study-of-ct120-in-patient-with-relapsedrefractory-b-cell-non-hodgkins-lymphoma-100446292","NCT05091541","A Phase 1\u002F2 Study of CT120 in Patient With Relapsed\u002FRefractory B-cell Non-Hodgkin's Lymphoma","A Multicenter Phase I\u002FII Clinical Study on Fully Human Anti-CD19\u002FCD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection (CT120) for the Treatment of Relapsed\u002FRefractory B-cell Non-Hodgkin's Lymphoma","Inclusion Criteria:\n\n1. Age between 18 and 70 years old.\n2. Pathologically confirmed B-cell non-Hodgkin's lymphoma, including:\n\n(1) Diffuse large B-cell lymphoma (DLBCL); (2) Histopathological Grade 3b follicular lymphoma (FL3b); (3) Follicular lymphoma with diffuse large B cell transformation; (4) Primary mediastinal large B-cell lymphoma (PMBCL). 3. Relapsed\u002Frefractory B-cell non-Hodgkin's lymphoma must meet one of the following criteria:\n\n1. At least 2 failed prior B-cell non-Hodgkin's lymphoma treatment regimens (including relapse, no response, and progression). Prior therapy must have included anti-CD20 monoclonal antibodies (except for CD20-negative subjects) and standard therapies which including anthracyclines;\n2. Recurrence after autologous hematopoietic stem cell transplantation;\n3. Primary resistance: After 2 cycles of initial anti-CD20 monoclonal immunochemotherapy, the best response was stable disease or disease progression.\n\n4\\. At least 1 measurable lesion as following:\n\n1. The long axis of the lymph node lesions should be ≥15mm (and the length of the short axis is measurable), or;\n2. The lengths of extra-lymph node lesions should be ≥10mm in both the long and short axis.\n\n5\\. Expected survival time≥12 weeks. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Adequate organ function before enrollment, and meet all the following laboratory test results:\n\n1. Blood routine: neutrophils ≥1.0 ×109\u002FL (granulocyte colony stimulating factor (G-CSF) is allowed within 7 days before the examination), lymphocytes ≥0.3 ×109 \u002FL, platelets ≥50 ×109 \u002FL (must have not received blood transfusion \\[including component transfusion\\] or treatments that include thrombopoietin \\[TPO\\] for the purpose of raising platelets within 7 days before the examination), hemoglobin ≥80g\u002FL (must have not received blood transfusion \\[including component blood transfusion\\] within 7 days before the examination);\n2. Blood coagulation function: fibrinogen≥1.0g\u002FL; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;\n3. Liver function: ALT and AST≤2.5×ULN; serum total bilirubin≤1.5×ULN;\n4. Renal function: creatinine clearance rate CrCl ≥60 mL\u002Fmin estimated by Cockcroft-Gault;\n5. Left ventricular ejection fraction (LVEF)≥50% estimated by echocardiography;\n6. Baseline oxygen saturation \\> 91% on room air. 8. Females and males with childbearing potential should take effective contraception from the day of signing the informed consent form to 365 days after the CT120 infusion. Effective contraception is defined as: abstinence or contraceptive methods with an annual failure rate of \\\u003C1% indicated in section 9.8 of this protocol.\n\n9\\. Subject is willing to participate in this trial and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Subjects who have received or require the following treatments:\n\n(1) Prior CAR-T cell therapy before enrollment; (2) Presence of acute or chronic graft-versus-host disease (GVHD) requires systemic treatment within 4 weeks before enrollment; (3) History of immunodeficiency or other diseases and autoimmune diseases (eg Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.) received immunosuppressive therapy within 2 years before enrollment; (4) Autologous hematopoietic stem cell transplantation (autoSCT) within 12 weeks before enrollment and history of allogeneic stem cell transplantation (HSCT); (5) Live vaccines injection within 4 weeks before enrollment; (6) According to investigator's discretion, there is a need to use systemic corticosteroid therapy within 12 weeks after the administration of the study drug (except for hydrocortisone ≤12mg\u002Fm2\u002Fday or other hormones converting into the same dose range for physiological replacement therapy) or other immunosuppressive drug therapy (except local therapy).\n\n2\\. B-cell non-Hodgkin's lymphoma patients with active central nervous system or intestinal parenchyma invasion.\n\n3\\. Excessive tumor burden and any lesions with a long axis ≥10cm. 4. Other active malignant tumors in the past 5 years, except for curable tumor that has been completely cured, such as basal or squamous cell carcinoma, cervical or breast carcinoma in situ, etc.\n\n5\\. Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and an abnormal HBV DNA result detected by peripheral blood test (abnormal HBV DNA result is defined as: the quantitative detection of HBV DNA is over the detectable lower limit or beyond the normal reference of the testing center or HBV viral DNA positive); Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA test positive; syphilis test positive.\n\n6\\. Uncontrollable active infections (except for genitourinary system infections and upper respiratory tract infections \\\u003C CTCAE Grade 2).\n\n7\\. Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ Grade III), severe arrhythmia.\n\n8\\. Hypertension that cannot be controlled by medication. 9. Adverse events during prior therapies have not relieved to baseline or ≤1 (according to NCI-CTCAE v5.0, except for alopecia).\n\n10\\. Major surgery within 2 weeks before enrollment, or surgeries that were planed while waiting for infusion or within 12 weeks after receiving investigational product (except planned local anesthesia surgery).\n\n11\\. History of organ transplant. 12. Pregnant or lactating women. 13. Previous central nervous system diseases (such as cerebral aneurysm, epilepsy, stroke, Alzheimer's disease, mental illness, etc.) or mental disorders.\n\n14\\. Unstable systemic diseases judged by other researchers: including but not limited to severe liver, kidney, or metabolic diseases that require medication.\n\n15\\. Other unsuitable situations for enrollment judged by investigators.","70 Years",{"count":221,"type":20},125,[74,23],"This study is a single-armed, open-label,multicenter Phase 1\u002F2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed\u002Frefractory B-cell non-Hodgkin's lymphoma.",[106],"2021-10-12",{"date":227,"type":55},"2021-10-25",{"date":229,"type":20},"2021-10-20",{"date":231,"type":20},"2039-10-20",{"name":233,"class":62},"Nanjing IASO Biotechnology Co., Ltd."]